AUTHORS
Kevin Liu, PharmD, Dale Chandler, MSc2, Louise O'Hara, PhD3, Claire Trennery, MSc4, Sonya Eremenco, MA5, David Cella, PhD6, Nati Lerman, MD7, Jonas S. Samuel Jutzi, PhD8, Kelly McQuarrie, BSN9
AFFILIATIONS
1 Merck & Co., Inc., Rahway, New Jersey, United States
2 Adelphi Values, Patient-Centered Outcomes, Bollington, Cheshire, United Kingdom
3 Adelphi Values, Patient-Centered Outcomes, Bollington, Cheshire, United Kingdom
4 Adelphi Values, Patient-Centered Outcomes, Bollington, Cheshire, United Kingdom
5 Critical Path Institute, Tucson, Arizona, United States
6 Northwestern University, Chicago, Illinois, United States
7 Merck & Co., Inc., Upper Gwynedd, Pennsylvania, United States
8 Merck & Co., Inc., Cambridge, Massachusetts, United States
9 Merck & Co., Inc., West Point, Pennsylvania, United States
ABSTRACT
Introduction: Essential thrombocythemia (ET) and polycythemia vera (PV) are myeloproliferative neoplasms that can substantially impact health-related quality of life (HRQoL). Robust patient-reported outcome (PRO) measures are essential to assess treatment benefit in ET and PV clinical research, however, limited evidence exists supporting the content validity of available PRO measures in these populations. This study aimed to characterize the symptoms and impacts on HRQoL in ET and PV and subsequently evaluate how well the Myelofibrosis Symptom Assessment Form (MFSAF v4.0) and the PROMIS-Fatigue SF-7a measures reflect those experiences.
Methods: Qualitative, semi-structured interviews were conducted with 36 U.S. participants with ET (first-line [1L], n=12; second/third-line [2L/3L], n=12) and PV (n=12) to understand what symptoms affected them the most and how their lives were impacted. The study was conducted in accordance with established qualitative research methodology and regulatory guidance for PRO research. Study materials were submitted for ethics review and approved. The concept elicitation section included open-ended questions exploring key symptoms and HRQoL impacts relevant to patients. The cognitive interviewing section included participants reviewing the PRO measures and providing feedback on relevance, comprehension, and completeness.
Results: Participant demographics were comparable across the 3 groups, with a mean age of 51.3–60.8 years, being predominantly female (58–67%), and with white/non-Hispanic representation ranging from 42–100%. Symptom burden was substantial, with the most reported symptoms overall including fatigue, night sweats, pain, itching, abdominal discomfort, headaches, and early satiety. Fatigue universally emerged as a core symptom, being reported by 100% of participants. Among participants who discussed symptom bothersomeness (n=32), fatigue was also most frequently identified as the most bothersome (1L ET: 50.0%, 2L/3L ET: 45.4%, PV: 81.8%). Among those asked about importance to treat, (n=27), fatigue was the most important symptom to treat (1L ET: 57.1%, 2L/3L ET: 40.0%, PV: 70.0%). Reporting of fatigue-related impacts was common across the groups and affected multiple functional domains, including physical functioning (83-100%), activities of daily living (75-100%), cognitive functioning (67-92%), and work functioning (67-83%).
Conceptual mapping was conducted to assess alignment between the concepts included in the MFSAF v4.0 and the major disease symptoms that participants described. Strong conceptual coverage was observed, with effective capture of fatigue, night sweats, itching, abdominal discomfort, early satiety, and bone pain. All groups consistently found the MFSAF v4.0 items clear and reflective of their disease experience. Participants reported on the relevance of individual symptoms in the MFSAF v4.0 measure, with fatigue considered the most relevant by all participants. Although a small number of additional symptoms were identified beyond those explicitly in the MFSAF v4.0, this did not materially diminish relevance of the measure.
For the PROMIS-Fatigue SF-7a measure, participants consistently found the items to be clear, relevant, and reflective of their fatigue experience. Conceptual mapping demonstrated strong alignment between the measure and participant-described experiences, capturing key fatigue-related concepts including tiredness, exhaustion, low energy, cognitive difficulties, and activity limitations. All groups similarly found the questions clear and reflective of their disease experience. Participant report of individual items in the PROMIS-Fatigue SF-7a was also high, with tiredness due to their condition being reported by all participants. The concepts assessed by the PROMIS-Fatigue SF-7a measure closely reflected how fatigue affected daily life.
Conclusion: This qualitative study provides evidence demonstrating that the MFSAF v4.0 and the PROMIS-Fatigue SF-7a measures align with participant experiences and effectively capture core symptoms and disease impacts relevant to ET and PV. The prominence of fatigue makes it a clear target for treatment and more in-depth assessment, among other key patient-endorsed symptoms. Consistent understanding and strong conceptual validity support the use of these PRO measures as endpoints for evaluating patient-relevant treatment benefit in ET and PV clinical trials.
DISCLOSURES
Kevin Liu, PharmD: Merck & Co - Current equity holder in publicly-traded company; Merck & Co - Current Employment